Publications in collaboration with researchers from Hospital Ramón y Cajal (24)

2024

  1. Clinical profile and outcomes in very elderly patients with atrial fibrillation anticoagulated with rivaroxaban: data from the EMIR study

    Journal of Geriatric Cardiology, Vol. 21, Núm. 7, pp. 723-732

  2. Invasive Treatment Strategy in Adults With Frailty and Non-ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of a Randomized Clinical Trial

    JAMA network open, Vol. 7, Núm. 3, pp. e240809

2023

  1. Adverse Clinical Outcomes and Associated Predictors in Rivaroxaban-Treated Atrial Fibrillation Patients With Renal Impairment

    American Journal of Cardiology, Vol. 203, pp. 122-127

  2. Changes in echocardiographic parameters over time in paradoxical low-flow low-gradient aortic stenosis

    European heart journal. Cardiovascular Imaging, Vol. 24, Núm. 8, pp. 1120-1128

  3. Effect of Routine Invasive vs Conservative Strategy in Older Adults With Frailty and Non-ST-Segment Elevation Acute Myocardial Infarction: A Randomized Clinical Trial

    JAMA Internal Medicine, Vol. 183, Núm. 5, pp. 407-415

  4. Myocardial injury after major non-cardiac surgery evaluated with advanced cardiac imaging: a pilot study

    BMC Cardiovascular Disorders, Vol. 23, Núm. 1

  5. Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban

    Journal of comparative effectiveness research, Vol. 12, Núm. 3, pp. e220049

2022

  1. Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study

    Cardiology Journal, Vol. 29, Núm. 6, pp. 936-947

  2. Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study

    Cardiology Journal, Vol. 29, Núm. 4, pp. 601-609

  3. Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry

    European heart journal. Cardiovascular pharmacotherapy, Vol. 9, Núm. 1, pp. 38-46

  4. Rivaroxaban for the prevention of outcomes in patients with atrial fibrillation in clinical practice: an indirect comparison of national and international registries

    Journal of comparative effectiveness research, Vol. 11, Núm. 16, pp. 1173-1184

  5. Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights

    Trials, Vol. 23, Núm. 1

  6. Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study

    European Journal of Clinical Investigation

2021

  1. Comorbidity burden and revascularization benefit in elderly patients with acute coronary syndrome

    Revista Espanola de Cardiologia, Vol. 74, Núm. 9, pp. 765-772

  2. Impact of comorbidities in the decision of using invasive management in elderly patients with NSTEACS

    REC: Interventional Cardiology, Vol. 3, Núm. 1, pp. 15-20

  3. In-hospital outcomes of mechanical complications in acute myocardial infarction: Analysis from a nationwide spanish database

    Cardiology Journal, Vol. 28, Núm. 4, pp. 589-597

  4. Prognosis impact of diabetes in elderly women and men with non-st elevation acute coronary syndrome

    Journal of Clinical Medicine, Vol. 10, Núm. 19

  5. Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: Impact of inappropriate doses (the EMIR study)

    Journal of Comparative Effectiveness Research, Vol. 10, Núm. 7, pp. 583-593

2019

  1. Atrial Fibrillation in Active Cancer Patients: Expert Position Paper and Recommendations

    Revista Espanola de Cardiologia, Vol. 72, Núm. 9, pp. 749-759

  2. Invasive Versus Conservative Strategy in Frail Patients With NSTEMI: The MOSCA-FRAIL Clinical Trial Study Design

    Revista Espanola de Cardiologia, Vol. 72, Núm. 2, pp. 154-159